IL33 and chronic obstructive pulmonary disease: For example, encouraging results have recently been obtained from phase 2 clinical trials showing that the use of the anti-IL-33 mAb, itepekimab, reduces the rate of exacerbation and improves lung function in former smokers with COPD [150].